CRH Medical (TSE:CRH) had its target price decreased by Acumen Capital from C$6.25 to C$6.00 in a report released on Friday morning.
Separately, TD Securities decreased their target price on CRH Medical from C$6.50 to C$5.50 and set a buy rating on the stock in a research note on Wednesday, January 9th.
CRH traded down C$0.09 on Friday, hitting C$3.87. 161,700 shares of the company’s stock traded hands, compared to its average volume of 132,590. The company has a market capitalization of $277.53 million and a PE ratio of 45.53. CRH Medical has a one year low of C$3.09 and a one year high of C$5.91. The company has a current ratio of 1.99, a quick ratio of 1.89 and a debt-to-equity ratio of 52.51.
CRH Medical (TSE:CRH) last issued its earnings results on Wednesday, March 13th. The company reported C$0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$0.03. The business had revenue of C$42.33 million for the quarter, compared to the consensus estimate of C$41.45 million. Equities research analysts predict that CRH Medical will post 0.10052770979038 earnings per share for the current year.
About CRH Medical
CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.
Read More: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.